| Gottlieb, Peter |
NCT03929601: Rituximab-pvvr and Abatacept Vs Rituximab-pvvr Alone in New Onset Type 1 Diabetes |
|
|
| Recruiting | 2 | 74 | US, RoW | Rituximab-pvvr, Ruxience, Abatacept, Orencia, Sterile Sodium Chloride, 0.9% Sodium Chloride Water for Injection | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institutes of Health (NIH) | Type 1 Diabetes Mellitus | 10/27 | 10/29 | | |
| Active, not recruiting | 1/2 | 120 | US | Siplizumab, TCD 601 | National Institute of Allergy and Infectious Diseases (NIAID) | Type 1 Diabetes Mellitus | 12/26 | 12/27 | | |
MER3101, NCT03624062: MAS-1 Adjuvanted Antigen-specific Immunotherapeutic for Prevention and Treatment of Type 1 Diabetes |
|
|
| Recruiting | 1 | 28 | US | MAS-1 adjuvanted Insulin B-chain | University of Colorado, Denver, The Leona M. and Harry B. Helmsley Charitable Trust, Nova Immunotherapeutics Limited | Type 1 Diabetes Mellitus | 12/25 | 12/25 | | |
| Recruiting | N/A | 111 | US | | National Institute of Allergy and Infectious Diseases (NIAID), Immune Tolerance Network (ITN) | Type 1 Diabetes Mellitus, T1DM, T1D | 03/25 | 03/25 | | |
| Esrey, Trudy |
DIAGNODE-3, NCT05018585 / 2021-002731-32: A Phase III Study to Investigate If the Study Drug Diamyd Can Preserve Insulin Production and Improve Glycemic Control in Patients Newly Diagnosed with Type 1 Diabetes |
|
|
| Recruiting | 3 | 330 | Europe, US, RoW | Recombinant human glutamic acid decarboxylase (rhGAD65) formulated in Alhydrogel®, Diamyd, Colecalciferol 2000 IU, Divisun 2000 IU, Placebo | Diamyd Medical AB | Type 1 Diabetes Mellitus | 12/27 | 12/27 | | |
NCT05743244: Janus Kinase (JAK) Inhibitors to Preserve C-Peptide Production in New Onset Type 1 Diabetes (T1D) |
|
|
| Recruiting | 2 | 78 | US | Abrocitinib 200 MG Oral Tablet, CIBINQO, Ritlecitinib, Placebo | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Pfizer | Diabetes Mellitus, Type 1 | 06/26 | 06/27 | | |
NCT03929601: Rituximab-pvvr and Abatacept Vs Rituximab-pvvr Alone in New Onset Type 1 Diabetes |
|
|
| Recruiting | 2 | 74 | US, RoW | Rituximab-pvvr, Ruxience, Abatacept, Orencia, Sterile Sodium Chloride, 0.9% Sodium Chloride Water for Injection | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institutes of Health (NIH) | Type 1 Diabetes Mellitus | 10/27 | 10/29 | | |
| Active, not recruiting | 2 | 101 | US, RoW | Antithymocyte Globulin, Thymoglobulin, Placebo (for ATG) | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Diabetes Mellitus, Type 1 | 12/28 | 12/29 | | |
| Active, not recruiting | 1/2 | 120 | US | Siplizumab, TCD 601 | National Institute of Allergy and Infectious Diseases (NIAID) | Type 1 Diabetes Mellitus | 12/26 | 12/27 | | |
TOPPLE T1D, NCT04279613: A Multiple Ascending Dose Trial Investigating Safety, Tolerability and Pharmacokinetics of NNC0361-0041 |
|
|
| Completed | 1 | 47 | US | NNC0361-0041, Placebo | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Novo Nordisk A/S | Type I Diabetes | 08/23 | 04/24 | | |
| Recruiting | N/A | 111 | US | | National Institute of Allergy and Infectious Diseases (NIAID), Immune Tolerance Network (ITN) | Type 1 Diabetes Mellitus, T1DM, T1D | 03/25 | 03/25 | | |
| Recruiting | N/A | 75000 | Europe, Canada, US, RoW | | University of South Florida, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), American Diabetes Association, National Institute of Allergy and Infectious Diseases (NIAID), National Center for Research Resources (NCRR) | Diabetes Mellitus, Type 1 | 07/25 | 07/25 | | |
| Kinney, Mara |
| Recruiting | N/A | 111 | US | | National Institute of Allergy and Infectious Diseases (NIAID), Immune Tolerance Network (ITN) | Type 1 Diabetes Mellitus, T1DM, T1D | 03/25 | 03/25 | | |
| Broncucia, Hali |
| Active, not recruiting | 1/2 | 120 | US | Siplizumab, TCD 601 | National Institute of Allergy and Infectious Diseases (NIAID) | Type 1 Diabetes Mellitus | 12/26 | 12/27 | | |
MER3101, NCT03624062: MAS-1 Adjuvanted Antigen-specific Immunotherapeutic for Prevention and Treatment of Type 1 Diabetes |
|
|
| Recruiting | 1 | 28 | US | MAS-1 adjuvanted Insulin B-chain | University of Colorado, Denver, The Leona M. and Harry B. Helmsley Charitable Trust, Nova Immunotherapeutics Limited | Type 1 Diabetes Mellitus | 12/25 | 12/25 | | |
| Recruiting | N/A | 50 | US | Definity Suspension for Injection, DEFINITY | University of Colorado, Denver | Type1diabetes, Insulitis, Pancreas Inflamed | 09/25 | 09/25 | | |
